|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Among them, those most commonly implicated in both well-differentiated adenocarcinoma and poorly differentiated adenocarcinoma are inactivation (mutations and allele loss) of the p53 gene, and activation (abnormal expression and amplification) of the c-met gene.
|
8440743 |
1993 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The c-MET-encoded receptor is detectable only at low levels in the normal human exocrine pancreas, but it is up-regulated in the majority of pancreatic ductal adenocarcinomas.
|
7866999 |
1995 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
There was a clear relationship between c-met protein staining and higher grade adenocarcinomas (p < 0.001). c-met protein is frequently detected in PIN and higher grade prostate cancers; future studies should evaluate the biological significance of these findings.
|
7539865 |
1995 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, these results strongly suggest that tpr-met activation does not play a role in Caucasian gastric carcinogenesis, while overexpression of the c-met gene occurs in the majority of Caucasian gastric adenocarcinomas.
|
11523050 |
2001 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma.
|
15720819 |
2005 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.
|
17132227 |
2006 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma.
|
16426920 |
2006 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma.
|
16186806 |
2006 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Met receptor signaling: a key effector in esophageal adenocarcinoma.
|
17062664 |
2006 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
|
18093943 |
2007 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.
|
17459054 |
2007 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
[Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma].
|
18172343 |
2007 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET amplification and EGFR amplification showed a trend toward poor prognosis in adenocarcinomas.
|
18379349 |
2008 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
All the instances of MET activation occurred in patients with adenocarcinomas.
|
19096300 |
2009 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.
|
20934974 |
2010 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
However, true MET amplification was more frequent in patients with SCC than in those with adenocarcinoma.
|
20107422 |
2010 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
MET-amplified tumors were typically high-grade adenocarcinomas that presented at advanced stages (5%; n = 4 of 80).
|
22042947 |
2011 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
High MET gene dosage was significantly associated with higher tumor stage (stage I + II versus stage III + IV; p = 0.0254) and prior chemotherapy for stage III + IV adenocarcinoma patients (35.71% versus 7.41%; p = 0.0145) but not correlated with primary TKI resistance.
|
22052229 |
2011 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High level of MET and SOX2 expression were respectively demonstrated in ADCs and SCCs; MET activation was accompanied with exon 19 deletion in ADCs.
|
21687954 |
2011 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET-amplified tumors were typically high-grade adenocarcinomas that presented at advanced stages (5%; n = 4 of 80).
|
22042947 |
2011 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
c-MET/phospho-MET expression and MET BISH positivity were observed in 22.2%, 5.6%, and 10.9% of NSCLCs, respectively; they were more prevalent in ADCs (27.3%, 6.9%, and 11.5%, respectively) and sarcomatoid carcinomas (20.9%, 9.3%, and 36.6%, respectively) than in SCCs and large cell carcinomas.
|
22198430 |
2012 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET FISH positivity was a negative prognostic factor, especially in patients with adenocarcinoma histology (p=0.040), female gender (p=0.010), old age (p=0.084), and EGFR FISH negativity (p=0.020) at the univariate level but not at the multivariate level.
|
22207554 |
2012 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here we investigated the copy number of the MET gene and expression of MET and HGF in small pulmonary adenocarcinomas.
|
21872356 |
2012 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To investigate metastasis associated in colon cancer 1 (MACC1) and MET expression in colorectal adenoma, Tis, early-stage invasive (T1 and T2), and advanced adenocarcinoma with liver metastasis using immunohistochemistry.
|
24124150 |
2013 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET amplification was associated with adenocarcinomas (P = 0.007), high-grade tumors (P = 0.003), more sites of metastasis, higher BRAF mutation, and PTEN loss (all P < 0.05).
|
25326232 |
2014 |